In-Licensed Drugs Bring More Growth Than In-House, Study Shows
Executive Summary
Datamonitor Healthcare analysis finds that as companies across the biopharmaceutical industry rely increasingly on externally sourced assets, per-drug revenue bears out this strategy. Part one of a series on the review of the impact, and potential, of externalizing R&D.
You may also be interested in...
External R&D Is Up, But Which Companies Are Reaping The Most Benefit?
Amgen, Novartis and Lilly are projected to increase sales from externally sourced assets in the coming years, according to a Datamonitor Healthcare analysis, while other big pharma – including frequent acquirer Pfizer and smaller-deal-oriented Bristol – are expected to see that ratio decline compared to sales of internally developed drugs.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.